Since OCT1 has the ability to transport derivatives of cisplatin, as well as paclitaxel12, 36, it is possible that ovarian cancer patients expressing reduced levels of OCT1 are associated with poor outcome following chemotherapy. The gene discussed is SLC22A1; the disease is ovarian cancer.